The intracellular signalosome of PD-L1 in cancer cells

被引:207
作者
Escors, David [1 ,2 ]
Gato-Canas, Maria [1 ]
Zuazo, Miren [1 ]
Arasanz, Hugo [1 ,3 ]
Jesus Garcia-Granda, Maria [1 ]
Vera, Ruth [3 ]
Kochan, Grazyna [1 ]
机构
[1] Complejo Hosp Navarra, IdISNA, Navarrabiomed, Irunlarrea 3, Pamplona 31008, Navarra, Spain
[2] UCL, Rayne Inst, Div Infect & Immun, 5 Univ St, London WC1E 6JF, England
[3] Complejo Hosp Navarra, IdISNA, Oncol Dept, Irunlarrea 3, Pamplona 31008, Navarra, Spain
关键词
T-CELLS; B7-H1; EXPRESSION; TUMOR-CELLS; B7; FAMILY; IFN-GAMMA; PROGRAMMED CELL-DEATH-1; ACQUIRED-RESISTANCE; SIGNALING PATHWAYS; CARCINOMA PATIENTS; DOWN-MODULATION;
D O I
10.1038/s41392-018-0022-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Programmed cell death-1 ligand-1 (PD-L1) overexpression in cancer cells accelerates tumor progression. PD-L1 possesses two main pro-oncogenic functions. First, PD-L1 is a strong immunosuppressive molecule that inactivates tumor-specific T cells by binding to the inhibitory receptor PD-1. Second, PD-L1 function relies on the delivery of intrinsic intracellular signals that enhance cancer cell survival, regulate stress responses and confer resistance toward pro-apoptotic stimuli, such as interferons. Here, we review the current knowledge on intracellular signal transduction pathways regulated by PD-L1, describe its associated signalosome and discuss potential combinations of targeted therapies against the signalosome with PD-L1/PD-1 blockade therapies.
引用
收藏
页数:9
相关论文
共 113 条
  • [81] Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development
    Powles, Thomas
    Necchi, Andrea
    Rosen, Galit
    Hariharan, Subramanian
    Apolo, Andrea B.
    [J]. CLINICAL GENITOURINARY CANCER, 2018, 16 (02) : 117 - 129
  • [82] Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma
    Prat, Aleix
    Navarro, Alejandro
    Pare, Laia
    Reguart, Noemi
    Galvan, Patricia
    Pascual, Tomas
    Martinez, Alex
    Nuciforo, Paolo
    Comerma, Laura
    Alos, Llucia
    Pardo, Nuria
    Cedres, Susana
    Fan, Cheng
    Parker, Joel S.
    Gaba, Lydia
    Victoria, Ivan
    Vinolas, Nuria
    Vivancos, Ana
    Arance, Ana
    Felip, Enriqueta
    [J]. CANCER RESEARCH, 2017, 77 (13) : 3540 - 3550
  • [83] Advances in T-cell checkpoint immunotherapy for head and neck squamous cell carcinoma
    Qi, Xinmeng
    Jia, Bo
    Zhao, Xue
    Yu, Dan
    [J]. ONCOTARGETS AND THERAPY, 2017, 10 : 5745 - 5754
  • [84] Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma
    Ritprajak, Patcharee
    Azuma, Miyuki
    [J]. ORAL ONCOLOGY, 2015, 51 (03) : 221 - 228
  • [85] Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
    Rittmeyer, Achim
    Barlesi, Fabrice
    Waterkamp, Daniel
    Park, Keunchil
    Ciardiello, Fortunato
    von Pawel, Joachim
    Gadgeel, Shirish M.
    Hida, Toyoaki
    Kowalski, Dariusz M.
    Dols, Manuel Cobo
    Cortinovis, Diego L.
    Leach, Joseph
    Polikoff, Jonathan
    Barrios, Carlos
    Kabbinavar, Fairooz
    Frontera, Osvaldo Aren
    De Marinis, Filippo
    Turna, Hande
    Lee, Jong-Seok
    Ballinger, Marcus
    Kowanetz, Marcin
    He, Pei
    Chen, Daniel S.
    Sandler, Alan
    Gandara, David R.
    [J]. LANCET, 2017, 389 (10066) : 255 - 265
  • [86] Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
    Rizvi, Naiyer A.
    Hellmann, Matthew D.
    Snyder, Alexandra
    Kvistborg, Pia
    Makarov, Vladimir
    Havel, Jonathan J.
    Lee, William
    Yuan, Jianda
    Wong, Phillip
    Ho, Teresa S.
    Miller, Martin L.
    Rekhtman, Natasha
    Moreira, Andre L.
    Ibrahim, Fawzia
    Bruggeman, Cameron
    Gasmi, Billel
    Zappasodi, Roberta
    Maeda, Yuka
    Sander, Chris
    Garon, Edward B.
    Merghoub, Taha
    Wolchok, Jedd D.
    Schumacher, Ton N.
    Chan, Timothy A.
    [J]. SCIENCE, 2015, 348 (6230) : 124 - 128
  • [87] PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma
    Ruf, Melanie
    Moch, Holger
    Schraml, Peter
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2016, 139 (02) : 396 - 403
  • [88] Targeting the ATR-CHK1 Axis in Cancer Therapy
    Rundle, Stuart
    Bradbury, Alice
    Drew, Yvette
    Curtin, Nicola J.
    [J]. CANCERS, 2017, 9 (05):
  • [89] Sathianathen NJ, 2017, IMMUNOTARGETS THER, V6, P83, DOI 10.2147/ITT.S134850
  • [90] Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
    Sharma, Padmanee
    Hu-Lieskovan, Siwen
    Wargo, Jennifer A.
    Ribas, Antoni
    [J]. CELL, 2017, 168 (04) : 707 - 723